Participated · Series B · Jul 2024

博瑞迪 provides low-cost genotyping and targeted gene capture sequencing solutions focused on molecular breeding for plants and animals. The company owns two proprietary targeted capture technology systems, GenoPlexs and GenoBaits. Its technology emphasizes high capture efficiency, flexible marker and capture types, and low-cost customized services for customers. The article reports that 博瑞迪 completed a RMB 250 million Series B financing. Participating investors and deal advisors are listed in the financing announcement. The article does not disclose operating metrics, founding year, or detailed future plans. Boruidi Bio builds a fully domestic, closed‑loop molecular breeding detection platform spanning database, algorithms, reagents and automated testing equipment, anchored on its proprietary liquid‑phase capture sequencing and GBTS technical system. The company positions itself as a third‑party service platform providing standardized sampling, high‑throughput detection and bioinformatics to breeding enterprises, and reports enabling customers to shorten breeding cycles by >50%, raise selection accuracy by 20–30%, and cut costs by over 90%. Boruidi says it has supported nearly 300 breeding units across more than 60 species and amassed roughly 2.5 PB of genetic data and ~800 billion variant data points. The team is led by founder Zhang Jia‑nan and includes members with experience from BGI, 23mofang, Wageningen, Cornell and other institutions. Recent plans include continued R&D and iterative upgrades, construction of a gene‑editing platform, and domestic and overseas business expansion. Financially the company has completed multiple financings in the past 18 months totaling over ¥100M, and will use new proceeds to accelerate technology development and market expansion.

Led · Series B · Dec 2017

Oriental Qiyin provides clinical speech development screening, early intervention, clinical training, and autism intervention services for children. Founded in 2007, the company has grown into the country's largest specialist chain in its sector, operating 45 direct-run centers across more than 19 cities including Beijing, Shanghai, Shenzhen and Guangzhou. It employs over 1,200 professional rehabilitation therapists and has served more than 200,000 children to date. The company emphasizes clinical practice, curriculum R&D and professional talent training, including partnerships with the University of Newcastle (Australia) and Beijing Language and Culture University to build therapist training systems. Oriental Qiyin plans to continue expanding its nationwide direct-center network, extend its course offerings across different needs, and integrate big data and AI with clinical practice to create an online-plus-offline rehabilitation service ecosystem. The firm positions itself to localize international standards for speech and autism intervention while addressing a large national talent gap through systematic training and academic cooperation. 东方启音 offers professional speech-therapy services and training programs, delivering both online and offline courses that address oral muscle and cognitive development. Its therapies are applied to children with cerebral palsy, Down syndrome, hearing impairment, ADHD, developmental delay, and autism, and the company also provides language-improvement courses for typically developing children and rehabilitation programs for adults (stuttering, post-stroke aphasia, post-surgery). The company has imported and promoted international speech-therapy techniques and works with multiple international partners to professionalize training, devices, teaching materials and software. Strategic partnerships include STAR Autism Support (collaboration on Mandarin autism training courses since 2016) and the University of Newcastle to standardize local course standards and build data-driven training plans. 东方启音 runs multiple OST-STAR centers using standardized curricula and has participated in public welfare screening and early-intervention campaigns alongside charities. Financially, the company completed a $25.0M Series B financing, which management says will support continued growth and talent development.